Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanTIG-205: Ociperlimab + Tislelizumab + Chemotherapy in Advanced NSCLC
NCT05014815Phase 2Completed
- Sponsor
- BeiGene
- Start
- Nov 2021
- Primary completion
- Sep 2024
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 8
01
Overview
A Phase 2 trial of ociperlimab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Nov 2021; status: completed.
02
Drugs
ociperlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05014815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014815.